Patents by Inventor John Knopf

John Knopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ALK7:ActRIIB heteromultimers and uses thereof
    Patent number: 10227392
    Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 12, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay, Gang Li, Yossi Dagon, John Knopf
  • METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
    Publication number: 20190048063
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: July 30, 2018
    Publication date: February 14, 2019
    Applicants: Acceleron Pharma Inc., Ludwig Institute for Cancer Research Ltd.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
  • Method of identifying an agent that promotes bone growth or increases bone density
    Patent number: 10071135
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: September 11, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra
  • Compositions comprising ALK1-ECD protein
    Patent number: 10059756
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: August 28, 2018
    Assignee: Acceleron Pharma Inc.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
  • COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20180221447
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Inventors: Ravindra Kumar, John Knopf
  • ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF
    Publication number: 20180194828
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting hone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.
    Type: Application
    Filed: November 13, 2017
    Publication date: July 12, 2018
    Inventors: Jasbir Seehra, John Knopf, Kenneth M. Attie
  • METHODS AND COMPOSITIONS FOR INCREASING RED BLOOD CELLS
    Publication number: 20180186851
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: October 13, 2017
    Publication date: July 5, 2018
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
  • METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
    Publication number: 20180179293
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 28, 2018
    Applicants: Ludwig Institute for Cancer Research Ltd., Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
  • METHODS FOR INCREASING THERMOGENIC ADIPOCYTES
    Publication number: 20180162954
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Application
    Filed: September 13, 2017
    Publication date: June 14, 2018
    Applicant: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • BMPRII POLYPEPTIDES AND USES THEREOF
    Publication number: 20180086806
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type II (BMPRII) polypeptide binds to ligands including BMP10, BMP15, activin B and BMP9 and may be used to treat fibrotic and angiogenic disorders.
    Type: Application
    Filed: April 5, 2017
    Publication date: March 29, 2018
    Applicant: Acceleron Pharma, Inc.
    Inventors: Ravindra Kumar, John Knopf
  • COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20180050089
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Application
    Filed: July 14, 2017
    Publication date: February 22, 2018
    Inventors: Ravindra Kumar, John Knopf
  • ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND USES THEREOF
    Publication number: 20170354731
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 14, 2017
    Inventors: ASYA GRINBERG, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra
  • Methods for increasing red blood cell levels comprising administering BMP9
    Patent number: 9809636
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 7, 2017
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
  • ALK7 Binding Proteins and Uses Thereof
    Publication number: 20170306028
    Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
    Type: Application
    Filed: April 21, 2017
    Publication date: October 26, 2017
    Applicants: Acceleron Pharma Inc., Adimab, LLC
    Inventors: John KNOPF, Jonathan BELK, Nathan J. SHARKEY, Ravindra KUMAR, Asya GRINBERG, Dianne SAKO, Roselyne CASTONGUAY, Yossi DAGON
  • ALK7 ANTAGONISTS AND USES THEREOF
    Publication number: 20170306027
    Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 26, 2017
    Inventors: John Knopf, Ravindra Kumar, Asya Grinberg, Robert Scott Pearsall, Dianne S. Sako, Roselyne Castonguay, Gang Li, Yossi Dagon
  • Methods for increasing thermogenic adipocytes
    Patent number: 9790284
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Noda1, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: October 17, 2017
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • BMPRII POLYPEPTIDES AND USES THEREOF
    Publication number: 20170291933
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type II (BMPRII) polypeptide binds to ligands including BMP10, BMP15, activin B and BMP9 and may be used to treat fibrotic and angiogenic disorders.
    Type: Application
    Filed: April 5, 2017
    Publication date: October 12, 2017
    Applicant: Acceleron Pharma, Inc.
    Inventors: Ravindra Kumar, John Knopf
  • ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING MULTIPLE MYELOMA
    Publication number: 20170190784
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
    Type: Application
    Filed: January 11, 2017
    Publication date: July 6, 2017
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • METHOD OF PROMOTING BONE GROWTH BY AN ANTI-ACTRIIA ANTIBODY
    Publication number: 20170145085
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: September 28, 2016
    Publication date: May 25, 2017
    Inventors: John Knopf, Jasbir Seehra
  • ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING OR PREVENTING BREAST CANCER
    Publication number: 20170145074
    Abstract: In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.
    Type: Application
    Filed: November 30, 2016
    Publication date: May 25, 2017
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar